Dedifferentiated liposarcoma (DDLPS) has an appealing therapeutic target due to its CDK4 amplification on chromosome 12q. The understanding of geroconversion from quiescent cells to senescent cells defines a patient’s response to CDK4 inhibitors. This new observation will inform not only the ongoing phase III clinical trial of abemaciclib, but all future clinical trials in DDLPS.

Original languageEnglish
Pages (from-to)649-651
Number of pages3
JournalClinical Cancer Research
Issue number4
StatePublished - Feb 15 2024


Dive into the research topics of 'To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma'. Together they form a unique fingerprint.

Cite this